4 October 2023
Latham & Watkins Represents Vistagen in US$100 Million Underwritten Offering
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Christopher Lueking Lead | Latham & Watkins LLP | Partner | capital markets | Chicago |
| Scott Westhoff Lead | Latham & Watkins LLP | Partner | capital markets | Chicago |
| KC Sands | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Omeed Valipour | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Claudia Wang | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | FDA regulatory matters | Washington, D.C. |
| Monica Groat | Latham & Watkins LLP | Counsel | FDA regulatory matters | Washington, D.C. |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA regulatory matters | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare matters | Bay Area |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 100m (US$100 million)
- What the figure measures
- Issue size
- Client
- Vistagen Therapeutics, Inc.Issuer
- Counterparties
- Not stated